FDA, NIH Devise Regulatory Research Agenda, Look For Financing
This article was originally published in The Tan Sheet
Executive Summary
The budget sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin notes. The Institute of Medicine recommends more collaborations to strengthen the Clinical and Translational Science Awards program.
You may also be interested in...
Appropriations Negotiators Allow NIH Translational Science Center Launch
NIH receives more than $500 million to finance the National Center for Advancing Translational Science, created in the consolidated fiscal 2012 appropriations bill. Members of Congress cautioned that NCATS’ work to speed up drug development should not inhibit private efforts in the same arena.
NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots
The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.